Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
The journal Drugs published a systematic literature review of clinical outcomes related to switching between reference medicines and biosimilars and concluded “the risk of immunogenicity-related safety concerns or diminished efficacy is unchanged after switching from a reference biologic to a biosimilar medicine.”
[/membership]